Oruka Therapeutics (NASDAQ:ORKA) Rating Lowered to Sell at Wall Street Zen

by · The Cerbat Gem

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Sunday.

Several other equities analysts also recently commented on ORKA. Leerink Partners set a $120.00 target price on Oruka Therapeutics in a research report on Thursday, April 30th. BTIG Research reissued a “buy” rating and set a $151.00 price target on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Wedbush restated an “outperform” rating and issued a $165.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, August 11th. HC Wainwright restated a “buy” rating and issued a $120.00 price target on shares of Oruka Therapeutics in a research note on Monday, August 3rd. Finally, UBS Group upped their price objective on Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $134.30.

Get Our Latest Report on ORKA

Oruka Therapeutics Stock Performance

NASDAQ ORKA opened at $112.66 on Friday. The stock has a market cap of $7.46 billion, a PE ratio of -55.50 and a beta of -0.34. The firm has a 50-day moving average of $88.49 and a 200-day moving average of $63.36. Oruka Therapeutics has a 52-week low of $14.08 and a 52-week high of $113.04.

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). As a group, analysts predict that Oruka Therapeutics will post -2.27 EPS for the current fiscal year.

Insider Buying and Selling at Oruka Therapeutics

In related news, insider Joana Goncalves sold 7,947 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $69.28, for a total transaction of $550,568.16. Following the sale, the insider owned 32,718 shares of the company’s stock, valued at $2,266,703.04. This represents a 19.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Carl Dambkowski sold 105,000 shares of the stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $58.97, for a total value of $6,191,850.00. Following the sale, the director directly owned 73,743 shares in the company, valued at $4,348,624.71. This represents a 58.74% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 188,116 shares of company stock valued at $12,828,383 over the last ninety days. Company insiders own 23.49% of the company’s stock.

Hedge Funds Weigh In On Oruka Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Algert Global LLC grew its holdings in shares of Oruka Therapeutics by 3.5% during the 2nd quarter. Algert Global LLC now owns 5,380 shares of the company’s stock worth $512,000 after purchasing an additional 180 shares in the last quarter. Royal Bank of Canada increased its holdings in Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after buying an additional 365 shares during the period. Kennedy Capital Management LLC increased its holdings in Oruka Therapeutics by 0.9% in the 4th quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock valued at $1,476,000 after buying an additional 420 shares during the period. AlphaCentric Advisors LLC raised its position in shares of Oruka Therapeutics by 5.8% in the 1st quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock valued at $564,000 after buying an additional 626 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its position in shares of Oruka Therapeutics by 35.0% in the 4th quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock valued at $92,000 after buying an additional 788 shares in the last quarter. 56.44% of the stock is owned by institutional investors and hedge funds.

About Oruka Therapeutics

(Get Free Report)

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

Featured Articles